NCT02007629 - Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 18, 2014

Primary Completion Date

December 29, 2016

Study Completion Date

December 29, 2016

Conditions

Hypertension, Pulmonary

Interventions

DRUG

Riociguat (Adempas, BAY63-2521)

Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily

Trial Locations (27)

1070

Bruxelles - Brussel

3000

Leuven

8091

Zurich

12808

Prague

13005

Marseille

15212

Pittsburgh

27100

Pavia

30625

Hanover

38043

Grenoble

50924

Cologne

63110

St Louis

69126

Heidelberg

92093

La Jolla

93053

Regensburg

94275

Le Kremlin-Bicêtre

95817

Sacramento

52242-1089

Iowa City

02111

Boston

02903

Providence

H3T 1E2

Montreal

01307

Dresden

04103

Leipzig

00161

Rome

NE7 7DN

Newcastle upon Tyne

G81 4DY

Clydebank

NW3 2QG

London

SW3 6NP

London